AtriCure (ATRC) 44th Annual J.P. Morgan Healthcare Conference summary

Market Opportunity and Vision

• Targeting a $10 billion annual market in AFib treatment and post-surgical pain management, with projections exceeding $10 billion by 2030, up from $1 billion in 2010.

• Serving 58 countries globally, with all products manufactured in the U.S. and a leadership position in large, underserved patient populations.

• Cardiac surgery is the largest market, with less than 10% penetration and a $7 billion annual opportunity, targeting nearly 2 million patients annually.

• Pain management franchise addresses thoracotomy, sternotomy, and amputations, representing a $2 billion market and the fastest-growing segment.

• Focused on healing lives affected by AFib and post-surgical pain, with a robust product portfolio and innovation pipeline.

Clinical Needs, Product Solutions, and Standard of Care

• AFib affects over 59 million globally, increasing risks of stroke, heart failure, mortality, and dementia.

• Persistent post-surgical pain impacts 30–50% of patients, with significant opioid addiction rates after thoracic and lung surgeries.

• Key products include ablation systems, AtriClip devices, and cryoablation probes for pain management and cardiac procedures.

• Vision to establish ablation and AtriClip as standard care in cardiac surgery, supported by advancements in clinical guidelines and reimbursement codes.

• Cryo Nerve Block for pain management provides rapid pain control and reduced narcotic use.

Innovation, Clinical Evidence, and Product Pipeline

• Recent innovations like the EnCompass Clamp and Flex Mini have simplified procedures and accelerated growth.

• Major clinical trials (LeAAPS and BOX-NO-AF/BoxX-NOAF) aim to change standards of care, targeting stroke and AFib reduction in cardiac surgery patients, with global reach and robust enrollment.

• Cryo nerve block products, including cryoSPHERE MAX and Cryo XT, reduce procedure time and improve post-amputation recovery.

• Ongoing product launches, FDA clearances, and international expansion from 2015–2025, with a pipeline of next-gen devices and expanded indications.

• Continuous investment in R&D and clinical evidence to maintain market leadership and defend against competition.